NVP-BVU 972
NVP-BVU 972 Basic information
- Product Name:
- NVP-BVU 972
- Synonyms:
-
- 6-[[6-(1-Methyl-1H-pyrazol-4-yl)imidazo[1,2-b]pyridazin-3-yl]methyl]quinoline NVP-BVU972
- NVP-BVU 972
- NVP-BVU972
- 6-[[6-(1-Methyl-1H-pyrazol-4-yl)imidazo[1,2-b]pyridazin-3-yl]methyl]quinoline
- NVP-BVU972, >=98%
- NVP-BVU972;NVP-BVU 972
- CS-529
- Quinoline, 6-[[6-(1-methyl-1H-pyrazol-4-yl)imidazo[1,2-b]pyridazin-3-yl]methyl]-
- CAS:
- 1185763-69-2
- MF:
- C20H16N6
- MW:
- 340.38
- EINECS:
- 200-258-5
- Product Categories:
-
- Inhibitors
- Mol File:
- 1185763-69-2.mol
NVP-BVU 972 Chemical Properties
- Density
- 1.35
- storage temp.
- Store at -20°C
- solubility
- insoluble in H2O; ≥17 mg/mL in DMSO; ≥25.15 mg/mL in EtOH
- form
- solid
- pka
- 4.92±0.10(Predicted)
- color
- White to off-white
NVP-BVU 972 Usage And Synthesis
Uses
NVP-BVU972 exhibits strong inhibition towards MET kinase but displays low inhibition against other kinases including the most closely related kinase RON.
Biological Activity
nvp-bvu972 is a selective and potent inhibitor of c-met with ic50 of 14 nm. besides, nvp-bvu972 displays ic50 values more than 1000 nm in other kinases such as the most closely related kinase recepteur d'origine nantais (ron).c-met, also known as hepatocyte growth factor receptor, is a receptor tyrosine kinase that can be activated by hepatocyte growth factor/scatter factor (hgf/sf). it is a membrane protein which plays an essential role in embryonic development and wound healing.in the ebc-1, gtl-16, and mkn-45 human cancer cells, nvp-bvu972 potently inhibits the cell proliferation with ic50 values of 82, 66 and 32 nm, respectively. additionally, nvp-bvu972 treatment leads to the inhibition of the growth of the transformed mouse baf3 cells containing tpr-met kinase fusions with ic50 of 104 nm 1.in human sample, nvp-bvu972 treatment on cells expressing wild-type tpr-met resulted in a dose-dependent reduction in tpr-met phosphorylation. y1230h, d1228a, f1200i and l1195v mutations abrogate the tpr-met phosphorylation inhibition effect of nvp-bvu972 in baf3 tpr-met1.
target
Met
References
1. tiedt r, degenkolbe e, furet p, et al. a drug resistance screen using a selective met inhibitor reveals a spectrum of mutations that partially overlap with activating mutations found in cancer patients. cancer research. 2011;71(15):5255-5264.
NVP-BVU 972Supplier
- Tel
- sales@boylechem.com
- Tel
- 010-82848833 400-666-7788
- jkinfo@jkchemical.com
- Tel
- +86 (531) 88811783
- sales@trio-pharmatech.com (International market)
- Tel
- 0411-62910999 13889544652
- sales@meilune.com
- Tel
- 4000-027-021 |24 +86-13986109188 | +86-15623472865 | +81-08033611988
NVP-BVU 972(1185763-69-2)Related Product Information
- 1,2-Dihydro-5-methyl-2-phenyl-3H-pyrazol-3-one
- 5-Hydroxy-1-methylpyrazole
- GDC-0068
- Dovitinib
- Infigratinib
- TAE226 (NVP-TAE226)
- Luminespib
- 1-Methylpyrazole
- Binimetinib
- ARRY-424704, ARRY-704
- BKM120 (NVP-BKM120, Buparlisib)
- MLN0905
- 2-[[(1R)-1-[7-methyl-2-(4-morpholinyl)-4-oxo-4h-pyrido[1,2-a]pyrimidin-9-yl]ethyl]amino]benzoic acid
- Tozasertib
- R428
- Nutlin 3a
- 6-[2-tert-Butyl-5-(6-methyl-pyridin-2-yl)-1H-imidazol-4-yl]-quinoxaline
- 6-Amino-N-[3-[4-(4-morpholinyl)pyrido[3',2':4,5]furo[3,2-d]pyrimidin-2-yl]phenyl]-3-pyridinecarboxamide